RET and non-small cell lung carcinoma: In a single-center retrospective study of Korea, the efficacy of Vandetanib was compared to chemotherapy in 59 RET fusion NSCLC patients, the ORR was 15.8% in the Vandetanib group, while 63% in chemotherapy group.